MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis
Abstract Murine double minute 2 (MDM2) inhibitors have shown promising activity in TP53-wild type tumors and are under active investigation across a spectrum of malignancies. Herein, we report a 51-year-old female with MDM2-amplified, TP53-wild type adenoid cystic carcinoma who was treated with a MD...
Saved in:
Main Authors: | Vishesh Khanna, Gohar Eslami, Rochelle Reyes, Robert Diep, Sebastian Fernandez-Pol, Henning Stehr, Carlos Jose Suarez, Harlan Pinto, James M. Ford, Tian Yi Zhang, Christopher T. Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-025-00823-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The cell cycle regulatory gene polymorphisms TP53 (rs1042522) and MDM2 (rs2279744) in lung cancer: a meta-analysis
by: O. Bulgakova, et al.
Published: (2020-12-01) -
Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study
by: Bruno Fattizzo, et al.
Published: (2025-02-01) -
Genetic evidence for the causal effect of clonal hematopoiesis on pulmonary arterial hypertension
by: Jia-Yong Qiu, et al.
Published: (2025-01-01) -
Ezetimibe Anticancer Activity via the p53/Mdm2 Pathway
by: Charmy Twala, et al.
Published: (2025-01-01) -
CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease
by: Angela Todorovski, et al.
Published: (2025-01-01)